Your browser is no longer supported. Please, upgrade your browser.
Antares Pharma, Inc.
Index- P/E11.95 EPS (ttm)0.36 Insider Own3.00% Shs Outstand167.82M Perf Week4.82%
Market Cap728.93M Forward P/E16.54 EPS next Y0.26 Insider Trans-14.43% Shs Float165.14M Perf Month0.23%
Income62.40M PEG- EPS next Q0.02 Inst Own51.30% Short Float2.78% Perf Quarter9.85%
Sales158.60M P/S4.60 EPS this Y83.30% Inst Trans-0.09% Short Ratio5.43 Perf Half Y-4.61%
Book/sh0.75 P/B5.80 EPS next Y126.72% ROA34.20% Target Price6.50 Perf Year54.80%
Cash/sh- P/C- EPS next 5Y- ROE67.80% 52W Range2.55 - 5.07 Perf YTD9.02%
Dividend- P/FCF97.19 EPS past 5Y34.10% ROI37.40% 52W High-14.20% Beta1.47
Dividend %- Quick Ratio1.60 Sales past 5Y26.80% Gross Margin59.30% 52W Low70.59% ATR0.16
Employees185 Current Ratio1.90 Sales Q/Q27.20% Oper. Margin12.80% RSI (14)51.85 Volatility3.98% 3.71%
OptionableYes Debt/Eq0.33 EPS Q/Q252.30% Profit Margin39.30% Rel Volume0.42 Prev Close4.34
ShortableYes LT Debt/Eq0.12 EarningsMay 06 BMO Payout0.00% Avg Volume846.38K Price4.35
Recom1.50 SMA20-0.10% SMA502.90% SMA20010.87% Volume356,953 Change0.23%
Jul-16-21Initiated Truist Buy $7
Oct-23-17Reiterated H.C. Wainwright Buy $5 → $3.50
Jun-23-17Initiated H.C. Wainwright Buy $5
Apr-21-17Initiated Raymond James Strong Buy
May-28-15Initiated Jefferies Buy $5
May-18-15Initiated Piper Jaffray Overweight $3.50
Aug-08-13Reiterated Ladenburg Thalmann Buy $5 → $5.75
Jun-21-13Resumed Oppenheimer Outperform $6
Jul-22-21 08:30AM  
Jul-11-21 03:29AM  
Jul-07-21 08:30AM  
Jun-28-21 08:30AM  
Jun-22-21 09:00AM  
Jun-15-21 08:30AM  
Jun-05-21 03:19AM  
Jun-01-21 01:38AM  
May-26-21 08:30AM  
May-06-21 09:25AM  
May-03-21 08:30AM  
Apr-29-21 05:03PM  
Apr-28-21 08:30AM  
Apr-27-21 08:30AM  
Apr-26-21 08:30AM  
Mar-27-21 03:56AM  
Mar-02-21 08:25AM  
Mar-01-21 10:14AM  
Feb-24-21 11:51PM  
Feb-23-21 08:30AM  
Feb-17-21 08:30AM  
Jan-26-21 12:02AM  
Jan-11-21 08:00AM  
Dec-27-20 01:12AM  
Dec-16-20 11:36AM  
Nov-30-20 11:48PM  
Nov-23-20 04:05PM  
Nov-10-20 04:30PM  
Nov-05-20 10:31PM  
Oct-29-20 12:35PM  
Oct-22-20 08:30AM  
Oct-12-20 06:28PM  
Oct-06-20 07:39AM  
Oct-01-20 08:46AM  
Sep-08-20 08:00AM  
Sep-06-20 10:14AM  
Aug-10-20 07:00AM  
Aug-07-20 09:17AM  
Aug-06-20 07:00AM  
Aug-03-20 10:55AM  
Jul-30-20 07:00AM  
Jul-21-20 07:00AM  
Jul-20-20 07:00AM  
Jun-24-20 09:39AM  
Jun-22-20 11:48AM  
Jun-11-20 07:00AM  
May-28-20 07:07AM  
May-27-20 07:00AM  
May-26-20 12:36AM  
May-05-20 09:30PM  
Apr-28-20 07:00AM  
Mar-22-20 06:13AM  
Mar-03-20 07:00AM  
Mar-01-20 09:20AM  
Feb-26-20 07:00AM  
Feb-25-20 07:00AM  
Jan-27-20 07:00AM  
Jan-16-20 05:59AM  
Dec-14-19 05:20PM  
Dec-10-19 07:00AM  
Dec-06-19 07:00AM  
Dec-02-19 09:49AM  
Nov-27-19 05:51PM  
Nov-20-19 07:25AM  
Nov-19-19 07:00AM  
Nov-13-19 07:00AM  
Nov-09-19 08:03PM  
Nov-05-19 07:00AM  
Nov-01-19 11:49AM  
Oct-31-19 07:00AM  
Oct-29-19 07:00AM  
Oct-24-19 07:00AM  
Oct-17-19 06:55AM  
Sep-17-19 07:00AM  
Sep-11-19 11:50AM  
Aug-20-19 08:09AM  
Aug-14-19 02:14PM  
Aug-06-19 05:23PM  
Jul-30-19 07:00AM  
Jun-27-19 07:00AM  
Jun-26-19 02:08PM  
Jun-11-19 07:00AM  
Jun-06-19 11:45AM  
Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas. It develops, manufactures, and commercialize novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and for glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto injectors; and drug/device product for urologic oncology and endocrinology. The company have strategic alliances and partnership arrangements pharmaceutical companies, including Pfizer, Idorsia, Teva, and AMAG. Antares Pharma, Inc. was founded in 1978 and is headquartered in Ewing, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GUETH ANTONDirectorJul 08Sale4.29100,000429,000467,577Jul 09 05:08 PM
GUETH ANTONDirectorMay 04Option Exercise1.6640,00066,400542,125May 06 04:53 PM
GUETH ANTONDirectorApr 29Option Exercise1.6672,669120,631502,125May 03 05:56 PM
GARRITY THOMAS JDirectorMar 11Option Exercise1.1250,00056,000274,406Mar 12 07:04 PM
GARRITY THOMAS JDirectorMar 11Sale4.2850,000214,000224,406Mar 12 07:04 PM
APPLE ROBERT FPresident & CEOFeb 18Option Exercise0.88250,000220,0002,696,720Feb 19 07:11 PM
GRAHAM PETER JEVP General Counsel, SecretaryFeb 18Option Exercise1.1245,00050,400585,417Feb 19 07:07 PM
JACOB LEONARD SDirectorFeb 18Option Exercise2.2415,32134,319268,363Feb 19 07:08 PM
GRAHAM PETER JEVP General Counsel, SecretaryFeb 18Sale4.9345,000221,650540,417Feb 19 07:07 PM
JACOB LEONARD SDirectorFeb 18Sale5.0515,32177,371253,042Feb 19 07:08 PM
APPLE ROBERT FPresident & CEOFeb 18Sale5.00491,9602,459,9782,204,760Feb 19 07:11 PM
APPLE ROBERT FPresident & CEOFeb 17Option Exercise2.625,51914,4602,452,239Feb 19 07:11 PM
APPLE ROBERT FPresident & CEOFeb 17Sale4.755,51926,2152,446,720Feb 19 07:11 PM
GARRITY THOMAS JDirectorFeb 11Option Exercise1.1250,00056,000274,406Feb 12 06:53 PM
GARRITY THOMAS JDirectorFeb 11Sale4.6250,000231,000224,406Feb 12 06:53 PM
APPLE ROBERT FPresident & CEOFeb 10Option Exercise2.627,27819,0682,302,433Feb 10 08:11 PM
APPLE ROBERT FPresident & CEOFeb 10Sale4.757,27834,5702,295,155Feb 10 08:11 PM
APPLE ROBERT FPresident & CEOFeb 09Option Exercise2.6249,129128,7182,344,284Feb 10 08:11 PM
APPLE ROBERT FPresident & CEOFeb 09Sale4.7549,129233,3632,295,155Feb 10 08:11 PM
APPLE ROBERT FPresident & CEOFeb 08Option Exercise2.6233,57487,9642,328,729Feb 10 08:11 PM
APPLE ROBERT FPresident & CEOFeb 08Sale4.7533,574159,4762,295,155Feb 10 08:11 PM
GARRITY THOMAS JDirectorJan 11Option Exercise1.4470,000100,800274,406Jan 13 08:21 PM
GARRITY THOMAS JDirectorJan 11Sale4.0670,000283,900224,406Jan 13 08:21 PM
Powell Fred MExecutive Vice President & CFONov 12Buy2.8516,40046,740646,465Nov 16 07:04 AM